LEGUBETI Drug Patent Profile
✉ Email this page to a colleague
When do Legubeti patents expire, and when can generic versions of Legubeti launch?
Legubeti is a drug marketed by Galephar and is included in one NDA.
The generic ingredient in LEGUBETI is acetylcysteine lysine. There are three drug master file entries for this compound. Additional details are available on the acetylcysteine lysine profile page.
Summary for LEGUBETI
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
DailyMed Link: | LEGUBETI at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for LEGUBETI
US Patents and Regulatory Information for LEGUBETI
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Galephar | LEGUBETI | acetylcysteine lysine | FOR SOLUTION;ORAL | 215040-002 | Feb 13, 2024 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Galephar | LEGUBETI | acetylcysteine lysine | FOR SOLUTION;ORAL | 215040-001 | Feb 13, 2024 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |